These guidelines have been approved by the SAKK Breast Cancer Project Group and the Gynecological Cancers Working Group. This document reflects clinical and scientific advances as of the date of publication and is subject to change. BRCA1 and BRCA2 are the main genes involved in the hereditary breast and ovarian cancer syndrome with an autosomal dominant mode of inheritance. The frequency of germ-line BRCA1/BRCA2 pathogenic variants is about 1:400 to 1:800 among healthy women from the Western non-Jewish white population. Carrying a germ-line mutation in BRCA1 or BRCA2 is associated with 40% to 75% cumulative risk of developing breast cancer and 15% to 60% cumulative risk for ovarian cancer by age 70 years [1] . About 3-5% of all breast cancer and 10-15% of unselected invasive ovarian cancer cases are BRCA-related [2] . Other rare high-to moderate-risk inherited syndromes can associate breast or ovarian cancer [3, 4] .
The rapid translation of next generation or massively parallel sequencing technology in diagnostic laboratory has opened impressive perspectives by allowing to test for multiple genes in a single assay (gene panel or exome) with substantial reductions both in costs and turn-around time. Some important issues have also been raised by this technological revolution, e.g. clinical validity or clinical utility of several genetic results, or identification of multiple variants of uncertain clinical significance [5, 6] . In Switzerland, testing for genetic predisposition to hereditary breast/ovarian cancer, particularly BRCA1/ BRCA2, is available in a clinical setting. Cancer risk assessment and genetic counseling are mandatory before and after genetic testing (i.e. pre-and post-test counseling). This genetic analysis is covered by health insurances only after formal genetic counseling and informed consent according to the KVL/OPAS/ OPre art. 12d, let. f [7] . Twenty-five centres throug- 
Introduction

Swiss guidelines for genetic counseling and testing for breast and ovarian cancer predisposition
The present paper summarises the Swiss guidelines for genetic counseling and ultimately testing individuals with an increased probability for carrying mutations in high-risk breast/ovarian cancer predisposition genes, particularly BRCA1/BRCA2. Risk-assessment is mainly based on some particular personal and/or family history patterns on both side of the family, including: -early-age of onset of breast cancer; -number of breast cancer cases across generations; -bilateral breast cancer; -ovarian cancer: of note, peritoneal and fallopian tube cancers should be considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome; -ethnic origin: currently limited to Ashkenazi Jews in our population.
Adapted from recently published guidelines [3, 4, 8, 10, 12] , it is reasonable to refer individuals with the following personal and/or family history for genetic counseling and considering testing for high-risk predisposition genes, particularly BRCA1/BRCA2 (see box on the right). 
V. Ashkenazi Jewish heritage:
-Search for the 3 founder BRCA1 and BRCA2 pathogenic variants3 regardless of personal or family history;
VI. Family history only (i.e. unaffected individuals):
-One or more close relatives1 with breast or ovarian2 cancer fulfilling one of the above criteria (points II-IV).
1 Close relative is defined as a first-or a second-degree relative on the same side of the family.
-first-degree relatives: mother/father, sister/brother, daughter/ son; -second-degree relatives: grandparents, aunt/uncle, niece/ nephew, grandchildren. 2 Ovarian cancer also includes primary peritoneal cancer and fallopian tube cancer. 
Comments
Meeting one or more of these criteria warrants further personalized genetic risk assessment and genetic counseling which will cover explanation of inheritance pattern, available testing options, discussion of disease management, treatment, surveillance and prevention options. Consider referral of cases with a weaker history of breast cancer if there is a family history of pancreatic cancer or prostate cancer, particularly at an early age at diagnosis (≤ 60 years), or sarcoma < 45 years, or glioma, or childhood adrenal cortical carcinoma, or complicated patterns of multiple cancers at a young age. Particular clinical situations not included in one of the above criteria should be discussed individually, e.g. ductal carcinoma in situ (DCIS) at an early age of onset (< 40 years), small or uninformative families or adoption. Borderline ovarian tumour is not considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome. Among the Ashkenazi Jewish population, the 3 BRCA1 and BRCA2 founder pathogenic variants (BRCA1: c.68_69delAG, c.5266dupC; BRCA2: c.5946delT) account for 98-99% of mutations identified and are carried by about 2.6% (1/40) of this population. When an appropriate affected family member is unavailable, testing of a family relative without a cancer diagnosis should be considered. Genetic testing for adult onset diseases, such as BRCA1/BRCA2-related disorders, is not recommended in children <18 years. Genetic testing on formalin-fixed and paraffin-embedded tumoral tissue is yet feasible to identify mutations predictive of response to treatment, e.g. identification of somatic or potentially germ-line BRCA1 or BRCA2 pathogenic variants and decision to introduce platinum-based drugs or poly(ADP-ribose) polymerase inhibitors. Currently, this molecular approach does not replace the search for germ-line pathogenic variants based on a blood sample in the context of a suspicion of genetic predisposition to hereditary breast/ ovarian cancer.
Conclusion
Cancer genetic predisposition is a complex clinical and socio-psychological condition which requires harmonization in medical practice and close interdisciplinary collaboration. An adequate identification of individuals who can potentially benefit from genetic counseling and testing is the essential prerequisite for a positive risk/benefit ratio [9] . Health care professionals should therefore be aware of the personal and/or family history patterns that are associated with an increased risk for germ-line pathogenic variants to allow for the most effective management of hereditary breast and ovarian cancer families and the most efficient utilization of health care resources. 
